| Holly Ann Zywicke, MD | |
|
201 Governors Dr Sw Fl 1, Huntsville, AL 35801-5171 | |
| (256) 533-1600 | |
| (256) 539-0856 |
| Full Name | Holly Ann Zywicke |
|---|---|
| Gender | Female |
| Speciality | Neurosurgery |
| Experience | 19 Years |
| Location | 201 Governors Dr Sw Fl 1, Huntsville, Alabama |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184832990 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Huntsville Hospital | Huntsville, AL | Hospital |
| Marshall Medical Centers | Boaz, AL | Hospital |
| Helen Keller Hospital | Sheffield, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Huntsville Hospital Spine And Neuro Center | 7214221464 | 24 |
News Archive
The U.S. Food and Drug Administration today approved the Optimizer Smart system for treating patients with chronic, moderate-to-severe heart failure who are not suited for treatment with other heart failure devices such as cardiac resynchronization therapy to restore a normal timing pattern of the heartbeat.
arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced the successful second closing of its Series A equity financing round. The Company raised an additional EUR 3.0 million (~USD 4.5 million) from two leading life science investors, Credit Agricole Private Equity and VIB (the prestigious Flemish research institute).
Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.
ASH welcomed the Government's refreshed anti-illicit tobacco strategy launched today. The new strategy had been pre-announced in the Budget, which noted that it would not only protect public finances but also "help meet public health objectives by driving down smoking prevalence."
Follow-up care for breast cancer patients costs less if it is conducted by nurses rather than physicians, yet there is no difference in the patients' anxiety, depression, satisfaction or outcome, according to research presented today (Friday) at the 6th European Breast Cancer Conference (EBCC-6) in Berlin.
› Verified 2 days ago
| Entity Name | Huntsville Hospital Spine And Neuro Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407210925 PECOS PAC ID: 7214221464 Enrollment ID: O20160810001750 |
News Archive
The U.S. Food and Drug Administration today approved the Optimizer Smart system for treating patients with chronic, moderate-to-severe heart failure who are not suited for treatment with other heart failure devices such as cardiac resynchronization therapy to restore a normal timing pattern of the heartbeat.
arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced the successful second closing of its Series A equity financing round. The Company raised an additional EUR 3.0 million (~USD 4.5 million) from two leading life science investors, Credit Agricole Private Equity and VIB (the prestigious Flemish research institute).
Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.
ASH welcomed the Government's refreshed anti-illicit tobacco strategy launched today. The new strategy had been pre-announced in the Budget, which noted that it would not only protect public finances but also "help meet public health objectives by driving down smoking prevalence."
Follow-up care for breast cancer patients costs less if it is conducted by nurses rather than physicians, yet there is no difference in the patients' anxiety, depression, satisfaction or outcome, according to research presented today (Friday) at the 6th European Breast Cancer Conference (EBCC-6) in Berlin.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Holly Ann Zywicke, MD Po Box 2705, Huntsville, AL 35804 Ph: (256) 533-1600 | Holly Ann Zywicke, MD 201 Governors Dr Sw Fl 1, Huntsville, AL 35801-5171 Ph: (256) 533-1600 |
News Archive
The U.S. Food and Drug Administration today approved the Optimizer Smart system for treating patients with chronic, moderate-to-severe heart failure who are not suited for treatment with other heart failure devices such as cardiac resynchronization therapy to restore a normal timing pattern of the heartbeat.
arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced the successful second closing of its Series A equity financing round. The Company raised an additional EUR 3.0 million (~USD 4.5 million) from two leading life science investors, Credit Agricole Private Equity and VIB (the prestigious Flemish research institute).
Marcadia Biotech Inc. today announced that it has initiated a Phase 1 clinical trial of MAR701, a novel dual agonist of the incretin hormone receptors for glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP). Marcadia plans to initially develop this compound as a treatment for type 2 diabetes with once-weekly dosing. The Phase 1 trial will evaluate MAR701 in healthy volunteers at escalating dose levels.
ASH welcomed the Government's refreshed anti-illicit tobacco strategy launched today. The new strategy had been pre-announced in the Budget, which noted that it would not only protect public finances but also "help meet public health objectives by driving down smoking prevalence."
Follow-up care for breast cancer patients costs less if it is conducted by nurses rather than physicians, yet there is no difference in the patients' anxiety, depression, satisfaction or outcome, according to research presented today (Friday) at the 6th European Breast Cancer Conference (EBCC-6) in Berlin.
› Verified 2 days ago
Dr. Joel D Pickett, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 201 Governors Drive 1st Floor, Huntsville, AL 35801 Phone: 256-533-1600 Fax: 256-539-0856 | |
Dr. Robert L Hash Ii, M.D. Neurological Surgery Medicare: Medicare Enrolled Practice Location: 10000 Serenity Lane S.e., Huntsville, AL 35803 Phone: 256-650-1212 Fax: 256-880-2929 | |
Dr. Jason T Banks, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 201 Governors Drive, 1st Floor, Huntsville, AL 35801 Phone: 256-533-1600 Fax: 256-539-0856 | |
Dr. Moneeb M. Ehtesham, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 201 Governors Dr Sw Fl 1, Huntsville, AL 35801 Phone: 256-533-1600 Fax: 256-539-0856 | |
Derrick H Cho, M.D. Neurological Surgery Medicare: Medicare Enrolled Practice Location: 201 Governors Dr Sw, Floor 1, Huntsville, AL 35801 Phone: 256-533-1600 Fax: 256-539-0856 | |
Dr. Cheng W Tao, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 201 Governors Drive, 1st Floor, Huntsville, AL 35801 Phone: 256-533-1600 Fax: 256-539-0856 |